Navigation Links
PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
Date:2/9/2009

SAN DIEGO, Feb. 9 /PRNewswire/ -- PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced today that it has recently completed a collaboration with LigoCyte Pharmaceuticals, Inc. Under the collaborative agreement, PacificGMP produced master cell and baculovirus banks and will provide storage services under cGMP (current good manufacturing practices) standards for LigoCyte's norovirus vaccine program. Furthermore, PacificGMP conducted the services under an accelerated timeline.

"We are pleased that LigoCyte chose PacificGMP to produce the master cell and baculovirus banks that will be used to produce their next-generation, intra-muscular norovirus vaccine candidate," said Leigh N. Pierce, President of PacificGMP. "The timeline specified in this agreement further demonstrates the time saving advantages of single-use technology as we were able to quickly initiate this project in order to assist LigoCyte in maintaining its program schedule."

"Through their diligent efforts, PacificGMP demonstrated their GMP proficiency and allowed us to maintain our program timelines," said Bryan Steadman, Senior Director of CMC Operations for LigoCyte. "We appreciate PacificGMP's assistance in the development of our vaccine for norovirus infection, an illness that afflicts an estimated 23 million individuals in the U.S. annually, frequently resulting in serious medical consequences."

About PacificGMP

PacificGMP is a contract manufacturer and industry leader in single-use technology for development and manufacturing of biologics. Single-use technology eliminates the risk of cross-contamination, has fewer system requirements and significantly reduces the time required to initiate production. Benefits to clients include rapid project turnaround and the most cost effective solution in the industry. PacificGMP partners with drug developers by providing a range of cGMP and non-GMP services from cell line optimization, early process design, development, purification and scale-up, to preclinical and clinical manufacturing, aseptic filling, testing, analytical services and regulatory support. More information can be found by visiting the Company's web site at www.PacificGMP.com.

About LigoCyte Pharmaceuticals

LigoCyte Pharmaceuticals is a private biopharmaceutical company focused on the development of innovative vaccine products based on the company's proprietary virus-like particle platform technology. LigoCyte's lead candidate recently completed a Phase I clinical trial. The vaccine is being developed for the prevention of norovirus gastroenteritis, an illness that causes an estimated 64,000 hospitalizations and 900,000 clinical visits among children annually in the U.S, according to the CDC. LigoCyte also has a novel influenza vaccine in preclinical development that has, notably, demonstrated protection in ferrets across multiple influenza subtypes with a single VLP antigen. Incorporated in 1998, LigoCyte has 45 employees and is located in Bozeman, Montana. Please visit www.ligocyte.com for more information.

    Contact:

    PacificGMP
    Gary Pierce
    Chief Business Officer
    858-550-4094

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Leigh Pierce

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=67271


'/>"/>
SOURCE PacificGMP
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
2. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
3. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
4. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
5. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
6. Tigris Pharmaceuticals Files IND Application for GGTI-2418
7. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
8. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
9. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
11. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016 Biocom, the association representing the ... a group of San Diego companies ... its 2016 Precision Medicine Advocacy Fly-In. Biocom Fly-In participants had ... Drug Administration (FDA), the Centers for Medicare and Medicaid Services ... San Diego U.S. Representatives Susan Davis and ...
(Date:2/12/2016)... 12, 2016  PTC Therapeutics, Inc. (NASDAQ: ... (Strategies to Realize Innovation, Vision and Empowerment) grant ... provides funds to patient advocacy organizations to develop ... contributions to the rare disease community by increasing ... patient advocates. Mary Frances Harmon ...
(Date:2/11/2016)... -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial ... --> --> For the fourth ... million, or $0.34 loss per share, compared to a net loss ... period in 2014. For the year ended December 31, 2015, the ... per share, as compared to a net loss of $60.5 million, ...
(Date:2/11/2016)... -- Bioethics International, a not-for-profit organization focused on the ethics and ... accessible to patients around the world, today announced that the ... of the Good Pharma Scorecard an ,Editors, ... one of BMJ Open ,s ,Most Popular Articles, which ... frequently read. Ed Sucksmith , assistant editor of ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
Breaking Biology News(10 mins):